18 Jun FDA Approves Twice-Yearly Shot for HIV Prevention

By Mike Bassett, MedPage Today

The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents, Gilead Sciences announcedopens in a new tab or window on Wednesday.

An injectable HIV-1 capsid inhibitor, lenacapavir marks the first and only twice-yearly PrEP option available in the U.S.

“Yeztugo could be the transformative PrEP option we’ve been waiting for — offering the potential to boost PrEP uptake and persistence and adding a powerful new tool in our mission to end the HIV epidemic,” said Carlos del Rio, MD, of Emory University School of Medicine in Atlanta, in a statement. Read more…